Janssen to Showcase Robust Oncology Portfolio at ESMO 2018 Congress

San Francisco, CA USA (UroToday.com) --  The Janssen Pharmaceutical Companies of Johnson & Johnson will present updates from across its oncology portfolio at the European Society for Medical Oncology (ESMO) 2018 annual congress, taking place on 19-23 October in Munich, Germany. Phase 3 data from the SPARTAN study reporting health-related quality of life outcomes in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide will be included in a poster session, with a further poster session highlighting data for ZYTIGA®  (abiraterone acetate) in metastatic hormone-sensitive prostate cancer. For erdafitinib in metastatic bladder cancer, a poster session will include an overview of the Phase 3 clinical trial design, and results from a Phase 2a study in advanced cholangiocarcinoma will be featured in a poster discussion.

Abstracts include clinical updates across solid tumor targeted therapies
  • Quality of life outcomes from Phase 3 SPARTAN clinical trial of apalutamide in non- metastatic castration-resistant prostate cancer
  • Practice informing PSA dynamics data from pivotal Phase 3 LATITUDE trial assessing ZYTIGA® plus prednisone and Androgen Deprivation Therapy (ADT) in metastatic hormone-sensitive prostate cancer
  • Presentation of erdafitinib Phase 3 study design in metastatic or surgically unresectable (M/UR) urothelial carcinoma
“We are proud to share such robust data and across a range of tumor types at this year’s ESMO congress,” said Dr. Ivo Winiger-Candolfi M.D., Europe, Middle East and Africa Oncology Solid Tumor Therapy Area Lead, Cilag GmbH International. “We are particularly excited to present health-related quality of life data from the SPARTAN trial, results that were recently published in The Lancet Oncology. Transforming patient outcomes is a key commitment for us at Janssen, and helping patients maintain quality of life while on treatment can be as important as their clinical outcome.”
Company-sponsored abstracts to be presented at the meeting include:


Abstract #804P : “Health-Related Quality of Life (HRQoL) After Progressive Disease (PD) in SPARTAN: a Phase 3 Trial of Apalutamide (APA) Versus Placebo (PBO) in Men with Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)” 
Poster display session Monday 22 October 12:45 - 13:45 Hall A3

Abstract #806P : “Relationship Between Apalutamide (APA) Exposure and Metastasis-Free Survival (MFS) in Patients (pts) With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From SPARTAN”

Poster display session Monday 22 October Time: 12:45 - 13:45 Hall A3

Abstract #797PD : “LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression- free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT + abiraterone acetate and prednisone (AAP) or placebo (PBO)”
Poster discussion session - genitourinary tumours, prostate (ID 167) Sunday 21 October 09:15 - 10:30 ICM - Room 14b

Abstract #920TiP : “Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Patients (pts) With Metastatic or Surgically Unresectable (M/UR) Urothelial Carcinoma(UC) and Selected FGFR Gene Alterations (FGFRalt): the Phase 3 THOR Study”
Poster display session Monday 22 October 12:45-13:45 Hall A3

Abstract #624PD : “Preliminary Results of a Phase2a Study to Evaluate the Clinical Efficacy and Safety of Erdafitinib in Asian Patients with Biomarker-Selected Advanced Cholangiocarcinoma (CCA)” 
Poster discussion session: gastrointestinal, non- colorectal 1 (ID 261) Friday 19 October 15:45 - 17:20 Hall B3 - Room 21


Abstract #834P : “Interim Results of a Phase 1b Study of Niraparib plus Androgen Receptor- Targeted Therapy in Men with Metastatic Castration-Resistant Prostate Cancer” 
Poster display session Monday 22 October 12:45-13:45 Hall A3

Abstract #1497P “JNJ-61186372 (JNJ-372), an EGFR-cMET Bispecific Antibody, in Advanced Non- Small Cell Lung Cancer (NSCLC): An Update on Phase 1 Results”
Poster display session Saturday 20 October 12:30-13:30 Hall A3

VELCADE® (bortezomib) : 
Abstract #1004O : “Final Overall Survival Results of Frontline Bortezomib plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) vs R-CHOP in Transplantation-ineligible Patients (Pts) with Newly Diagnosed Mantle-Cell Lymphoma (MCL): A Randomized, Open- Label, Phase 3 (LYM3002) Study” Proffered paper session Sunday 21 October 11:00 – 11:15 Hall A3

Further Related Content:
Complete ESMO 2018 Conference Coverage

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.